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1160Objective: Myocardial infarction leads to contractile dysfunction. In patients with diabetes, impaired contrac-
tility has been associated with the loss of insulin effects and mitochondrial dysfunction. We assessed cardiac
insulin sensitivity and mitochondrial and contractile function in rats after ligation of the left coronary artery.
Methods: At 2 weeks after left coronary artery ligation, we performed echocardiography in vivo and assessed
the substrate use and insulin response in the isolated working heart and the regulation of insulin (Akt, glucose
transporter type 4) and mitochondrial signaling (p38 mitogen-activated protein kinase, peroxisome proliferator-
activated receptor-g coactivator 1a, mitochondrial transcription factor A) using polymerase chain reaction and
Western blotting.
Results: The infarcted hearts were dilated and had a reduced ejection fraction (ejection fraction<50%). The
basal glucose oxidation was preserved, but the fatty acid oxidation was significantly reduced. Insulin’s effect on
substrate oxidation was significantly impaired for both the decrease in fatty acid oxidation and the increase in
glucose oxidation. However, insulin-stimulated glucose uptake was normal in the infarcted hearts, consistent
with normal insulin-induced phosphorylation of Akt and unchanged mRNA expression of glucose transporter
type 4. The impaired oxidative response to insulin was associated with reduced mRNA expression of the genes
regulating fatty acid oxidation (long-chain-acyl-coenzyme A dehydrogenase, carnitine palmitoyltransferase 1,
peroxisome proliferator-activated receptor-a) and mitochondrial biogenesis (mitochondrial transcription factor
A). Although mRNA expression of the mitochondrial master regulator peroxisome proliferator-activated recep-
tor-g coactivator 1a was normal in the infarcted hearts, the protein expression of its post-transcriptional activa-
tor, p38 mitogen-activated protein kinase, was significantly reduced.
Conclusions: Myocardial infarction in rats caused partial insulin resistance at the level of substrate oxidation,
whichwas associatedwithmitochondrial andcardiac contractile dysfunction.Mitochondrial dysfunctionwas char-
acterized by a reduced capacity to oxidize fatty acids and might have resulted from impaired mitochondrial bio-
genesis through the lack of p38 mitogen-activated protein kinase. (J Thorac Cardiovasc Surg 2010;140:1160-7)Myocardial infarction is the main cause of heart failure in
the Western world.1 The onset of heart failure after infarc-
tion is thought to occur because of a series of cellular
changes leading to cardiac dysfunction, a process termede Department of Cardiac Surgery,a University of Leipzig Heart Center,
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The Journal of Thoracic and Cardiovascular Sur‘‘remodeling.’’2 Although this concept has been long known,
the mechanisms involved in this setting are still unclear. Dif-
ferent mechanisms have been suggested as a cause of cardiac
dysfunction. Several investigators have described ‘‘energy-
starvation’’ concepts, implying the lack of adenosine tri-
phosphate as a determinant of pump failure.3,4 These
concepts brought the focus to the adenosine triphosphate-
generating machinery of the cell (ie, the mitochondria) and
the components regulating its function.
Insulin, in addition to affecting substrate selection, can in-
fluence mitochondrial biogenesis and function. The link be-
tween the loss of insulin’s effects and impaired heart
function has received specific attention with the recognition
of diabetic cardiomyopathy.5 Studies in mouse models with
a specific knockout of the cardiac insulin receptor (CIRKO
mice) showed mitochondrial dysfunction and cardiomyopa-
thy, suggesting cardiac insulin resistance as a potential mech-
anism for contractile dysfunction.6 However, whether
cardiac insulin resistance is involved in infarction-induced
contractile dysfunction is unknown. Therefore, we assessedgery c November 2010
Abbreviations and Acronyms
CPT-1 ¼ carnitine palmitoyltransferase 1
GLUT4 ¼ glucose transporter type 4
MAPK ¼ mitogen-activated protein kinase
LCAD ¼ long-chain-acyl-coenzyme A
dehydrogenase
PGC-
1a
¼ peroxisome proliferator-activated
receptor-g coactivator 1a
PPARa ¼ peroxisome proliferator-activated
receptor-a
Tfam ¼ mitochondrial transcription factor A
Amorim et al Evolving Technology/Basic Sciencethe cardiac insulin response and cardiac contractile andmito-
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Materials
The chemicals were obtained from Sigma Aldrich (Deisenhofen,
Germany), Merck (Darmstadt, Germany), Serva (Heidelberg, Germany),
Essex (Mu¨nchen, Germany), Bayer (Leverkusen, Germany), Narkodorm-
n (Neumu¨nster, Germany), Cell Signalling (Frankfurt amMain, Germany),
and Bio-Rad Laboratories (Mu¨nchen, Germany).
Animals and Surgical Interventions
Male Sprague-Dawley rats (weight 200–300 g) were obtained from
Charles River Laboratories (Sulzfeld, Germany) or from the animal facility
of the University of Leipzig and were fed ad libitum with free access to
water at 21C with a light cycle of 12 hours. The Animal Welfare Commit-
tee of the University of Leipzig (Leipzig, Germany) approved the use of the
rats and the experimental protocols.
The infarct model in rats has been previously described in detail.7 To in-
duce myocardial infarction, the rats were anesthetized with fentanyl, mid-
azolam, and medetomidin (0.005 mg fentanyl/kg, 2 mg midazolam
hydrochloride/kg, and 0.15 mg medetomidin hydrochloride/kg intramus-
cularly), intubated with 16-gauge tubing, and ventilated with room air
(1 mL/100 g, 96 breaths/min). Lateral thoracotomy was performed, and, af-
ter visualization of the heart, the pericardium was gently open. The left
coronary artery was localized using the pulmonary artery and the left
atrium as anatomic markers. A 6-0 Prolene suture line was then used to
ligate the coronary. After the thorax and skin were closed, the rats were
extubated and kept on warming pads for the recovery periods. Age-
matched, sham-operated rats that had undergone the same procedure with-
out coronary occlusion were used as the control group.
After 2 weeks, echocardiography was conducted, and the hearts were
harvested and used for the isolated working heart perfusion experiment
(set 1), insulin stimulation ex vivo (set 2), or polymerase chain reaction
and Western blot assessment (set 3). For sets 2 and 3, the hearts were ex-
cised and weighed. The scar tissue was macroscopically resected and
weighed before the hearts were snap-frozen in liquid nitrogen. The scar
areas were determined as the percentage of scar weight in relation to the
heart weight. The scar area was not used for additional analysis.
Echocardiography
The rats were anesthetized with fentanyl, midazolam, andmedetomidin,
their chests were shaved, and they were examined in the supine position
with a 12-MHz phased array transducer (Agilent/Philipps, Hamburg,
Germany). Two-dimensional, parasternal, short-axis echocardiogramsThe Journal of Thoracic and Carwere obtained from the left ventricle at the papillarymuscle level. The frac-
tional shortening was determined according to Teichholz and colleagues,8
and the ejection fraction was calculated according to Simpson’s rule. Echo-
cardiographic examinations were performed in 9 rats from the infarct group
and 10 rats from the control group.
Isolated Working Heart Perfusion
The preparation for the isolated working heart perfusion has been pre-
viously described in detail.9,10 The rats were anesthetized with sodium
pentobarbital (5 mg/100 g body weight intraperitoneally). After injection
of heparin (200 IU) into the inferior vena cava, the heart was rapidly
removed and placed in ice-cold Krebs-Henseleit bicarbonate buffer. The
aorta was cannulated, and hearts were perfused as working hearts at
37C, with recirculating Krebs-Henseleit buffer (200 mL) containing 1%
bovine serum albumin, Cohn fraction V, fatty acid free (Celliance, Toronto,
Ontario, Canada). The perfusate calcium concentration was 2.5 mM. The
hearts were perfused with glucose (5 mM) and oleate (0.4 mM) as sub-
strates. The perfusate was gassed with 95% oxygen and 5% carbon diox-
ide, and recirculated. All experiments were performed with a preload of 15
cm H2O and an afterload of 100 cm H2O. After stabilization, the hearts
were perfused for 30 minutes, followed by an insulin addition (1 mU/
mL), and another 30 minutes of perfusion. In this period, all samples
were withdrawn and the measurements performed. The heart rate and sys-
tolic and diastolic aortic pressure were measured continuously using
a Hugo Sachs transducer and recording system (TAM-A type 705/1;
Hugo Sachs Elektronik, March-Hugstetten, Germany). The heart rate
was measured as the beats per minute and the cardiac output as millimeters
per minute. The cardiac power was determined as follows: [flow (mL/
min) 3 pressure (100 cm H2O)]/612 (correction factor).
Samples of the coronary effluent (2 mL) were withdrawn every 5 min-
utes for the assessment of glucose uptake and oxidation and fatty acid
oxidation. The different rates were determined from the production of
14CO2 from [U-14C] glucose and 3H2O from [9,10-3H] oleate or [2-
3H] glucose. These radioactive substrates allow the precise determination
of glucose uptake ([2-3H] glucose), glucose oxidation ([U-14C] glucose)
and fatty acid oxidation ([9,10-3H] oleate). Glucose and fatty acid oxida-
tion were determined simultaneously during 10 heart perfusions for the
control group and 9 for the infarct group. Glucose uptake was assessed
in a separate set of perfusions (n ¼ 5 in each group).
Quantitative Real-Time Polymerase Chain Reaction
Myocardial mRNA was isolated from frozen tissue samples using the
Qiagen RNeasy mini kit. Synthesis of complementary DNAwas performed
with the cDNA synthesis kit from Fermentas (St. Leon-Rot, Germany), and
TaqMan quantitative real-time reverse transcriptase-polymerase chain re-
action was performed using AmpliTaq Gold (ABI; Applyed Bio Systems,
Darmstadt, Germany), with the conditions suggested by the manufacturer,
on the ABI 7900 HT, as previously described.11 Forward and reverse
primers were designed using the Universal Probe Library Assay Design
Center. For each set of primers, a basic local alignment search tool search
revealed that sequence homology was obtained only for the target gene.
The reaction mixture consisted of 1 mL diluted template, 0.025 U/mL Taq
Polymerase, 0.01 U/mL AmpErase, 5.5 mM MgCl2, 200 mM dNTP mix,
13 TaqMan buffer A, 200 nM forward and reverse primers, and 100 nM
probe. The results were normalized to S29 transcription as a housekeeping
gene product, which was not different by experiment among all samples.
The numbers of rats included ranged from 7 to 11 in each group.
Insulin Stimulation Ex Vivo
The hearts were harvested according to the protocol for the isolated
working heart. After cannulation of the aorta, the hearts were retro-
gradely perfused with Krebs-Henseleit buffer at 37C containing 5
mM glucose in the presence or absence of insulin (1 mU/mL) fordiovascular Surgery c Volume 140, Number 5 1161
TABLE 1. Heart, lung, and body weights and fractional scar content
of rats 2 weeks after left coronary artery ligation or sham operation
Variable Sham group Infarct group P value
BW (g) 287  5 308  10 .05
HW (mg) 1513  65 1639  108 .31
HW/BW ratio 6.58  0.07 6.23  0.18 .77
LW/BW ratio 4.28  0.10 4.22  0.10 .68
Scar area (%) NA 7.20  0.74 NA
Data are presented as mean  standard error of mean; n ¼ 6–10/group. Scar area de-
termined by macroscopically excising scar tissue and weighing it in relation to heart
weight. BW, Body weight;HW, heart weight;HW/BW, heart weight/body weight; LW/
BW, lung weight/body weight; NA, not applicable.
TABLE 2. Cardiac size and function 2 weeks after left coronary artery
ligation
Variable
Sham group
(n ¼ 6–10)
Infarct group
(n ¼ 6–10)
P
value
Heart rate (beats/min) 270  6 283  8 .21
LVEDD (mm) 7.33  0.16 9.62  0.17 < .001
LVPWD (mm) 1.86  0.18 1.75  0.17 .66
LVPWS (mm) 2.72  0.14 2.36  0.08 < .001
Ejection fraction (%) 68.0  2.6 36.1  3.1 < .001
Fractional shortening (%) 41.4  1.4 18.5  1.8 .04
Cardiac power ex vivo (mW/g dry) 31.6  1.8 22.9  3.8 .03
Data are presented as mean  standard error of mean. LV, Left ventricle; LVEDD, LV
end-diastolic diameter; LVPWD, LV posterior wall in diastole; LVPWS, LV posterior
wall in systole.
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blotting.
Immunoblotting
Western blots were performed on a semidry Western blot apparatus.
After sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the pro-
teins were blotted to a polyvinyldine diflouride membrane and incubated
with primary and secondary antibodies. The bands were visualized and
semiquantified by chemiluminescence using AIDA software. At the end,
the membrane was dyed with naphthol blue black solution to visualize
the proteins and then used to normalize the band intensity. For Western
blotting, the number of rats used was 8 for each group.
Statistical Analysis
The data are presented as the mean  standard error of the mean. The
data were analyzed using one-way analysis of variance or Student’s
t test, as appropriate. Post hoc comparisons among the groups were
performed using the Holm-Sidak test.RESULTS
Table 1 lists the heart, lung, and body weight of the in-
farcted and sham-operated groups. The rats with infarction
weighed 7% more than the sham-operated rats. The heart
weights were not significantly different between the 2
groups. The heart/body weight ratios were also normal in
the infarct group, and no evidence was seen of pulmonary
edema or significant pulmonary congestion, as demon-
strated by the normal lung/body weight ratios. The macro-
scopically identified scar area caused by left coronary artery
ligation was similar among the rats, with values of 5.6% to
9.8% of the total heart weight. The mortality after left cor-
onary artery ligation was 17%. Of those that died, 12% had
died perioperatively and the other 5% during the 2-week
follow-up period.
Table 2 lists the echocardiographic parameters of the in-
farcted and sham-control groups. No difference was seen in
the heart rate between the infarcted and control rats. Myo-
cardial infarction led to significant dilation of the left ven-
tricle, as demonstrated by a significant increase in the left
ventricular end-diastolic diameter. The infarcted rat hearts
had contractile dysfunction with a reduced left ventricular
posterior wall at systole, ejection fraction, and fractional1162 The Journal of Thoracic and Cardiovascular Surshortening (14%, 52%, and 45% less than that of the con-
trol rats, respectively). Ex vivo evaluation of cardiac func-
tion in the isolated working heart system also revealed
impaired cardiac contraction (45% lower than in the
sham-operated groups). No evidence of hypertrophy was
seen 2 weeks after infarction, as demonstrated by the nor-
mal left ventricular posterior wall in diastole and heart/
body weight ratios.
Figure 1 shows the substrate oxidation rates in the
isolated working heart in the basal state and after insulin
addition. Basal glucose oxidation was normal after infarc-
tion. However, fatty acid oxidation was significantly re-
duced at the basal levels. The insulin-induced stimulation
of glucose oxidation and inhibition of fatty acid oxidation
were significantly blunted at 2 weeks after infarction. The
impairment in insulin response was evident from both the
effect on the absolute values and the percentage of basal
rates. In contrast to the oxidation rates, glucose uptake
was normal both before and after insulin stimulation
(Table 3). No evidence was seen for a lack of insulin
response at this level, whether the insulin-induced increase
was expressed in absolute values or as a percentage of the
baseline values.
Insulin’s effect on glucose uptake is mainly mediated
through Akt-stimulated glucose transporter type 4
(GLUT4) translocation.12 Akt is also a mediator of hyper-
trophy.13 Akt can be activated through phosphorylation at
serine 473 and/or threonine 308 in response to insulin or
hypertrophic stimuli.14 Figure 2 shows the total Akt expres-
sion and the phosphorylated fraction of Akt, with or without
insulin stimulation, at both Akt phosphorylation sites. The
total Akt level was normal in the infarcted hearts. Consis-
tent with the lack of hypertrophy and the normal glucose up-
take in the infarcted hearts, the basal and insulin-induced
phosphorylation were the same in infarcted hearts and in
those from the control group.
Figure 3 shows the mRNA expression of the genes
involved in substrate use and the regulation of mitochon-
drial biogenesis. Although GLUT4 expression was normalgery c November 2010
FIGURE 1. Substrate oxidation rates of isolated working rat hearts from rats that underwent left coronary artery ligation or a sham procedure and their
response to insulin. A, Rates of basal and insulin-stimulated glucose oxidation. Insulin-stimulated increase in glucose oxidation as B, absolute values
and C, percentage of basal rates. D, Rates of basal and insulin-stimulated fatty acid oxidation. Insulin-stimulated decrease in fatty acid oxidation as E,
absolute values and F, percentage of baseline. Open bars indicate sham control group; solid bars, infarct group. Values presented as mean standard error
of mean; n ¼ 5 to 7 per group. *P<.05 compared with control, #P<.05 compared with basal values of same group.
Amorim et al Evolving Technology/Basic Science(Figure 3, A), a significant reduction was seen in the mRNA
expression of carnitine palmitoyltransferase 1 and long-
chain-acyl-coenzyme A dehydrogenase (Figure 3, B and
C), which regulate mitochondrial fatty acid uptake and ox-
idation, respectively. These alterations are consistent with
the reduced fatty acid oxidation rates of the infarcted hearts
when perfused as isolated working hearts (Figure 1). Im-
paired fatty acid oxidation was also supported by the re-
duced expression of peroxisome proliferator-activated
receptor-a (PPARa) (Figure 3, D), the main transcription
factor for all fatty acid oxidation genes (including long-
chain-acyl-coenzyme A dehydrogenase). The expression
of mitochondrial transcription factor A (Tfam) (Figure 3,
E), the transcription factor regulating the expression of
the mitochondrial genome (exclusively genes for the respi-
ratory chain), was also significantly reduced. PPARa andTABLE 3. Glucose uptake of infarcted isolated working rat hearts 2
weeks after left coronary artery ligation with or without insulin
stimulation
Glucose uptake
Sham group
(n ¼ 5)
Infarct group
(n ¼ 5)
P
value
Basal (mmol/min/g dry) 1.62  0.22 2.36  0.70 .35
Insulin-stimulated (mmol/min/g dry) 3.36  0.38 3.46  0.93 .92
Change
Absolute value (mmol/min/g dry) 1.73  0.29 1.09  0.48 .29
% 113  24 68  22 .21
Data are presented as mean  standard error of mean.
The Journal of Thoracic and CarTfam are both targets of peroxisome proliferator-activated re-
ceptor-g coactivator 1a (PGC-1a), a metabolic co-activator
and master mitochondrial regulator.15 PGC-1a is regulated
at both transcriptional and post-transcriptional levels.
Figure 3,F shows thatmRNAexpression of PGC-1awas nor-
mal 2 weeks after infarction. However, Figure 4 reveals a sig-
nificant decrease in protein expression of p38 mitogen-
activated protein kinase (MAPK), a post-transcriptional acti-
vator of PGC-1a.16E
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We have demonstrated that myocardial infarction in rats
causes partial insulin resistance at the level of substrate ox-
idation in the remote myocardium. This cardiac insulin re-
sistance is associated with mitochondrial and contractile
dysfunction. Mitochondrial dysfunction is characterized
by reduced fatty acid oxidation capacity and might be due
to impaired mitochondrial biogenesis through a lack of
p38 MAPK. The results suggest a role for cardiac insulin
resistance and mitochondrial defects in ventricular remod-
eling and contractile dysfunction after myocardial infarc-
tion. If true, treatment of cardiac insulin resistance might
improve contractile function and thereby help improve
cardiac surgery outcomes because the preoperative ejection
fraction is inversely correlated with perioperative mortal-
ity.17 Several aspects of our findings require additional
discussion.diovascular Surgery c Volume 140, Number 5 1163
FIGURE 2. Basal and insulin-stimulated phosphorylation of Akt in infarcted and sham control hearts. A, Total protein expression of Akt. Level of phos-
phorylated Akt at B, Ser473 and C, Thr308 with (hatched bars) and without (solid bars) insulin stimulation in control and infarcted hearts.White solid bars
indicate control group without insulin; light-hatched bars, control group with insulin; black solid bars, infarct group without insulin; and dark-hatched bars,
infarct groupwith insulin. RepresentativeWestern blots shown. Values presented as mean standard error of mean; n¼ 4 per group. #P<.05 compared with
levels without insulin from same group.
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and contractile dysfunction has been developed from the
recognition that systemic insulin resistance predicts the
heart failure incidence independently of diabetes and other
established risk factors for heart failure.18 Although strong
clinical evidence exists for this relationship, less is known
about the underlying mechanisms. The term ‘‘systemic in-FIGURE 3. mRNA expression of genes involved in substrate use and mitochon
A, glucose transporter type 4 (GLUT4); B, carnitine palmitoyltransferase 1 (CP
isome proliferator-activated receptor-a (PPARa); E, mitochondrial transcripti
coactivator 1a (PGC-1a). Values are presented as mean  standard error of m
1164 The Journal of Thoracic and Cardiovascular Sursulin resistance’’ previously mentioned refers to impair-
ment in insulin-stimulated glucose use, mainly in the
skeletal muscle and adipose tissue. The heart is an
insulin-sensitive organ; however, whether cardiac insulin
resistance needs to be present when systemic insulin resis-
tance is present is still unclear. In vivo studies of patients
with diabetes using fluorodeoxyglucose-positron emissiondrial biogenesis in infarcted and sham-control hearts. mRNA expression of
T-1); C, long-chain-acyl-coenzyme A dehydrogenase (LCAD); D, perox-
on factor A (Tfam); and F, peroxisome proliferator-activated receptor-g
ean, n ¼ 8 to 10 per group. *P<.05 compared with control group.
gery c November 2010
FIGURE 4. Protein expression of p38 mitogen-activated protein kinase
(MAPK) in sham-operated control and infarcted hearts. RepresentativeWest-
ern blots shown. Values presented as mean  standard error of mean, n ¼ 4
per group. *P<.05 compared with control group.
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stimulated myocardial glucose uptake19; however, the re-
sults are questionable owing to methodologic limita-
tions.20,21 In contrast, animal models of systemic insulin
resistance develop myocardial insulin resistance.22 Cardiac
insulin resistance induced by specific knockout of the insu-
lin receptor in the heart resulted in mitochondrial and con-
tractile dysfunction.6 Thus, cardiac insulin resistance might
represent a potential mechanism for heart failure by causing
mitochondrial dysfunction.
We have demonstrated that myocardial infarction re-
sulted in an impaired insulin response at the level of sub-
strate oxidation but normal insulin-stimulated glucose
uptake, supported by the unchanged insulin-induced Akt
phosphorylation and normal GLUT4 gene expression. Al-
though insulin-stimulated glucose uptake has been widely
used as a marker for insulin sensitivity, insulin exerts
many more effects on the substrate metabolism. For in-
stance, insulin can boost glycolysis and glucose oxidation
independently of glucose uptake.23 Insulin can also activate
glycogen synthesis and, importantly, insulin resistance in
those with type 2 diabetes mellitus has been shown to be
characterized by impaired glucose oxidation and glycogen
synthesis, although glucose uptake is normal.24 Other than
its acute effects on the glucose metabolism, insulin
regulates the expression of genes involved in cell growth
and mitochondrial biogenesis.25 Therefore, impairment of
insulin’s effects can develop at different levels, leading to
partial insulin resistance. Thus, assessing insulin-
stimulated glucose uptake and Akt phosphorylation alone
might not fully reflect insulin sensitivity.The Journal of Thoracic and CarWe had opted to perform our investigations at 2 weeks
after inducing infarction, because it was our goal to assess
the early changes in cardiac metabolism and insulin sensi-
tivity after infarction. One other study has investigated
cardiac insulin sensitivity of the heart 10 weeks after myo-
cardial infarction.26 The investigators found reduced
insulin-stimulated glucose uptake and reduced GLUT4
expression. Although they did not assess insulin’s effect
on substrate oxidation, it is tempting to speculate that our
observation of a reduced insulin effect on substrate oxida-
tion and normal uptake response 2 weeks after infarction
reflects the beginning of insulin resistance that could get
worse during continued postinfarct remodeling.
The diminished insulin response at the level of substrate
oxidation was associated with mitochondrial dysfunction. A
standard method for the characterization of mitochondrial
function is the measurement of the maximal respiratory ca-
pacity in isolated mitochondria. In the present study, we did
not evaluate the mitochondrial respiration; thus, one could
question the presence of mitochondrial dysfunction. How-
ever, we showed an overall decrease in fatty acid oxidation,
which could be explained by the downregulation of carni-
tine palmitoyltransferase 1 and long-chain-acyl-coenzyme
A dehydrogenase, as well as their transcriptional activator,
the nuclear receptor, PPARa. These alterations reflect true
impairment in mitochondrial oxidative function in vivo,
a situation that justifies the use of the term ‘‘mitochondrial
dysfunction.’’ In addition to oxidative dysfunction, mito-
chondrial biogenesis could also be impaired. This is charac-
terized by reduced gene expression of Tfam, which plays
a critical role in the construction of the respiratory chain
complexes.27 Both PPARa and Tfam are downstream tar-
gets of PGC-1a, the master metabolic co-activator govern-
ing substrate use and mitochondrial biogenesis.15 We found
no change in PGC-1a mRNA levels. However, the regula-
tion of PGC-1a is highly complex. Its activity is not only
controlled by the levels of gene or protein expression but
also by post-translational modification. The phosphoryla-
tion and acetylation status affects the activity of PGC-1a
significantly, but inhibition of PGC-1a through its repressor
is also an important mechanism. The binding of the repres-
sor to PGC-1a can be counteracted by p38 MAPK.16
Furthermore, exercise has been shown to activate PGC-1a
downstream targets in skeletal muscle through p38
MAPK, without increasing PGC-1a protein levels.28 In
the present study, we showed decreased protein expression
of p38 MAPK in association with downregulation of the
PGC-1a downstream targets (PPARa, Tfam). These data
would support the reduction in PGC-1a signaling at the
post-translational level, leading to impaired mitochondrial
biogenesis and oxidative function.
In contrast to these interpretations, the coexistence of
a reduced cardiac insulin response at the level of substrate
oxidation and mitochondrial dysfunction could also bediovascular Surgery c Volume 140, Number 5 1165
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ence of cardiac insulin resistance in our model. It is possible
that a defect in the mitochondrial oxidative machinery
results in a reduced ability to increase glucose oxidation af-
ter insulin stimulation. This would mean that the attenuated
cardiac insulin response would only be an expression of
impaired oxidative capacity but not of insulin resistance.
However, 2 considerations argue against this interpretation.
First, the response to insulin of both glucose and fatty acid
oxidation were diminished. Thus, by definition, insulin
resistance is present. Second, the basal rates of glucose
oxidation in our model were normal, indicating competent
glucose oxidative capacity and not impairment. Therefore,
we believe that cardiac insulin resistance exists independent
of mitochondrial oxidative defects.
The final issue requiring discussion is the relationship
between cardiac insulin resistance and mitochondrial dys-
function. As mentioned, cardiac insulin resistance might
cause mitochondrial and contractile dysfunction. Further-
more, it has recently been shown that impaired cardiac
insulin signaling in CIRKO mice accelerated the develop-
ment of mitochondrial dysfunction and worsened survival
after myocardial infarction despite an equivalent infarct
size.29 However, whether partial cardiac insulin resistance
2 weeks after infarction causes mitochondrial dysfunction
and contributes to ventricular remodeling remains unclear
and warrants additional studies. Although cardiac insulin
resistance could also be considered an epiphenomenon in
this case, it can be seen as a marker for mitochondrial dys-
function and the ventricular remodeling process and could
may thus serve as a risk factor for infarction-induced car-
diac dysfunction.
CONCLUSIONS
Myocardial infarction in rats causes partial insulin resis-
tance at the level of substrate oxidation, associated with mi-
tochondrial and cardiac dysfunction. Mitochondrial
dysfunction is characterized by a reduced capacity to oxi-
dize fatty acids possibly because of impaired mitochondrial
biogenesis through decreased p38 MAPK signaling.
We thank Anja Koeppen for technical assistance.
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Dr Todd Rosengart (Stony Brook, NY). I would like to congrat-
ulate the authors on a nice presentation. This is obviously an im-
portant clinical problem in the context of the prevalence of
diabetes in the western world and increasing heart failure as
a potential complication of this incidence.
My question goes to a little bit of the ‘‘cart–before-the-horse’’
dilemma. You created a model where you clearly demonstrate in-
sulin resistance and then subsequent heart failure, but I am not
quite sure that you have demonstrated a causal effect as opposed
to an intermediate step in your described pathophysiologic pro-
cess. So, I was wondering if you have thought about challenging
your system with antihyperglycemic rescue agents that can reverse
insulin resistance to show whether you can prevent heart failure in
your model system as a means of validating your hypothesis.
Dr Amorim. That is a very good point. Actually, there is a work
from Rong Tian inCirculation last year in which they used metfor-
min in infarcted rats and they found an improvement in survival,
although they only focused on AMPK activation. And, actually,
that is work in progress for us now; we are trying to see if metfor-
min or pioglitazone can improve cardiac function.
Dr Rosengart. Similarly, you mentioned that you began to look
at levels of Akt. You can similarly either downregulate Akt with
wortmannin or even potentially upregulate this system with gene
transfer of AKT as an alternative way of preventing your CHF
phenotype, so that may also help further prove that the insulinThe Journal of Thoracic and Carresistance is causal rather than maybe just an intermediate step.
Have you considered manipulating AKT in your models?
Dr Amorim. Well, the causal role is actually the focus of our
work now. But the point is that, even if cardiac insulin resistance
predisposes or is caused by contractile dysfunction, the focus is
that it is present in contractile dysfunction and it could be used
as a marker of heart failure.
Dr Rosengart. And, similarly, have you considered looking at
diabetic models as opposed to physiologic injury for your stimula-
tor of injury, in OB mice or the like?
Dr Amorim. Yes. But it is difficult to separate the vascular
commitment from the muscular.
Dr Rosengart. My last question is: In your abstract, you men-
tion that you measured dyspnea in the rats as a parameter. So, I just
needed to know how you assessed dyspnea in a rat; I was fasci-
nated by that.
Dr Amorim.Well, I can show some photos where you can see
that they are really blue and they are really short of breath and it is
easy to recognize, actually, if you see one.
Dr Pedro J. del Nido (Boston, Mass). One brief question. Mi-
tochondria seems to be a common theme here in a lot of the chronic
heart failure and also even in the ischemia-reperfusion models.
Insulin obviously is a very important growth factor and also for
mitochondrial biogenesis. Have you looked at the mitochondrial
component of your heart failure model?
Dr Amorim. Yes, we are working on that now.diovascular Surgery c Volume 140, Number 5 1167
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